Prosecution Insights
Last updated: July 17, 2026
Application No. 18/739,456

SELF-SEALING CANNULA

Non-Final OA §102§DP
Filed
Jun 11, 2024
Priority
Nov 14, 2014 — provisional 62/079,876 +3 more
Examiner
DEAK, LESLIE R
Art Unit
Tech Center
Assignee
University of Maryland, Baltimore
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
710 granted / 943 resolved
+15.3% vs TC avg
Strong +18% interview lift
Without
With
+17.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
34 currently pending
Career history
982
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
72.3%
+32.3% vs TC avg
§102
7.0%
-33.0% vs TC avg
§112
0.9%
-39.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 943 resolved cases

Office Action

§102 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by US 2011/0054405 to Whiting et al. In the specification and figures, Whiting discloses the apparatus as claimed by Applicant. With regard to claims 1, 7, 8, 16, and 20, Whiting discloses a self-sealing cannula system comprising a first cannula 11 with proximal and distal ends, a flexible, self-sealing closure 10 attached to the cannula, wherein the closure comprises a hollow elongate structure formed by elastomeric membranes 13, 14, wherein cannula 11 is attached to the interior membrane 14, and the valve comprises a self-sealing iris style shutter 12 at an end of the cylindrical wall that seals upon withdrawal of the cannula (see FIGS 2, 6A, 6B and accompanying text, ¶0041-0042). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim1 of U.S. Patent No. 10,695,483 to Wu et al and claim 1 of US 12,005,177 to Wu et al. Although the claims at issue are not identical, they are not patentably distinct from each other for the flowing reasons: Instant claim 1 claims a self-sealing cannula system with an elongated first cannula, a flexible, self-sealing closure attached to the first cannula, the closure comprising a hollow elongate structure with an open interior and a self-sealing shutter, wherein the closure is configured to expand from a compressed state to an uncompressed state to seal against an interior of the cannula, wherein the shutter closes a central hole of shutter when the cannula is not inserted therethrough. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LESLIE R DEAK whose telephone number is (571)272-4943. The examiner can normally be reached Monday-Friday, 9am to 5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sarah Al-Hashimi can be reached on 571-272-7159. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LESLIE R DEAK/Primary Examiner, Art Unit 3799 30 June 2026
Read full office action

Prosecution Timeline

Jun 11, 2024
Application Filed
Jul 02, 2026
Non-Final Rejection mailed — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678550
NEW STANDARDIZATIONS & MEDICAL DEVICES FOR THE PREPARATION OF PLATELET RICH PLASMA (PRP) OR BONE MARROW CONCENTRATE (BMC) ALONE OR IN COMBINATION WITH HYALURONIC ACID
5y 0m to grant Granted Jul 14, 2026
Patent 12678328
INTRAOCULAR SHUNTS WITH LOW-PROFILE ACTUATION ELEMENTS AND ASSOCIATED SYSTEMS AND METHODS
3y 4m to grant Granted Jul 14, 2026
Patent 12667488
SHUNTING SYSTEMS WITH ROTATION-BASED FLOW CONTROL ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODS
3y 2m to grant Granted Jun 30, 2026
Patent 12661263
EYE SHUNT SYSTEM AND METHODS
3y 6m to grant Granted Jun 23, 2026
Patent 12661264
STENT IMPLANT FOR TREATING GLAUCOMA BY MEANS OF INTRAOCULAR FLUID DRAINAGE FROM THE ANTERIOR CHAMBER
3y 3m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
93%
With Interview (+17.6%)
3y 3m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 943 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month